Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?

Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?

Bibliographic Details
Main Authors:	Dave Singh, Gerard J. Criner, Ian Naya, Paul W. Jones, Lee Tombs, David A. Lipson, MeiLan K. Han
Format:	Article
Language:	English
Published:	BMC 2021-11-01
Series:	Respiratory Research
Online Access:	https://doi.org/10.1186/s12931-021-01894-7

Similar Items

Measuring disease activity in COPD: is clinically important deterioration the answer?
by: Dave Singh, et al.
Published: (2020-06-01)

Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis
by: MeiLan K. Han, et al.
Published: (2021-03-01)

Preventing clinically important deterioration with single-inhaler triple therapy in COPD
by: Ian Naya, et al.
Published: (2018-10-01)

Long-term outcomes following first short-term clinically important deterioration in COPD
by: Ian P. Naya, et al.
Published: (2018-11-01)

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol
by: Singh D, et al.
Published: (2016-06-01)

Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial
by: Klaus F. Rabe, et al.
Published: (2020-07-01)

Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis
by: Mona Bafadhel, et al.
Published: (2020-01-01)

Discordant diagnostic criteria for pneumonia in COPD trials: a review
by: Robert A. Wise, et al.
Published: (2021-11-01)

InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations
by: Dave Singh, et al.
Published: (2021-04-01)

Early and sustained symptom improvement with umeclidinium/vilanterol monotherapy in COPD: a analysis of the EMAX randomised controlled trial
by: Edward M Kerwin, et al.
Published: (2020-05-01)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
by: Nicola C. Day, et al.
Published: (2020-06-01)

Adding budesonide to formoterol reduces risk of clinically important deteriorations (CID) in moderate to very severe COPD
by: Bafadhel, M, et al.
Published: (2018)

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
by: Singh D, et al.
Published: (2019-02-01)

Impact of baseline COPD symptom severity on the benefit from dual mono-bronchodilators: an analysis of the EMAX randomised controlled trial
by: Claus F. Vogelmeier, et al.
Published: (2020-11-01)

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
by: Anzueto AR, et al.
Published: (2017-05-01)

Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis
by: Ian Naya, et al.
Published: (2019-03-01)

Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial
by: F. Maltais, et al.
Published: (2020-10-01)

Recommendations for the pharmacological treatment of COPD: questions and answers
by: Frederico Leon Arrabal Fernandes, et al.

Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
by: François Maltais, et al.
Published: (2019-10-01)

The Mechanisms of Benefit of High-Flow Nasal Therapy in Stable COPD
by: Massa Zantah, et al.
Published: (2020-11-01)

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
by: Antonio R. Anzueto, et al.
Published: (2018-06-01)

Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol
by: Dave Singh, et al.
Published: (2017-05-01)

Clinically Important Deterioration (CID) and Ageing in COPD: A Systematic Review and Meta-Regression Analysis According to PRISMA Statement
by: Manzetti GM, et al.
Published: (2023-10-01)

When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment
by: Cheng WC, et al.
Published: (2020-12-01)

Time‐Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial
by: Mark T. Dransfield, et al.
Published: (2022-09-01)

Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy
by: Dhungana S, et al.
Published: (2017-08-01)

Getting the Correct Answer
by: Gladys Sterenberg
Published: (2006-12-01)

DEFINITION OF TYPOS IN ANSWER OF STUDENT IN KNOWN CORRECT ANSWER
by: Maria V. Biryukova, et al.
Published: (2016-05-01)

Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries.
by: Jason Foo, et al.
Published: (2016-01-01)

Detection of acute deterioration in health status visit among COPD patients by monitoring COPD assessment test score
by: Pothirat C, et al.
Published: (2015-02-01)

Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema
by: Massa Zantah, et al.
Published: (2020-06-01)

Late Breaking Abstract - Protection by budesonide against clinically important deteriorations (CID) in patients with COPD is dependent on blood eosinophil counts (EOS)
by: Bafadhel, M, et al.
Published: (2018)

One‐year clinically important deterioration and long‐term clinical course in Japanese patients with COPD: a multicenter observational cohort study
by: Yuki Abe, et al.
Published: (2021-05-01)

COPD in symptomatic aortic stenosis: the importance of correct assessment for defining prognosis
by: Rigolli, M, et al.
Published: (2018)

COPD in symptomatic aortic stenosis: the importance of correct assessment for defining prognosis
by: Rigolli, M, et al.
Published: (2018)

Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis
by: Yogesh Suresh Punekar, et al.
Published: (2017-05-01)

Croup – the most important questions and answers
by: Adam J. Sybilski
Published: (2019-05-01)

Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma
by: Umme Kolsum, et al.
Published: (2017-04-01)

THE IMPORTANCE OF EARLY DETECTION OF COPD
by: Tanja Gržetić Romčević, et al.
Published: (2008-02-01)

Efficacy and safety profile of xanthines in COPD: a network meta-analysis
by: Mario Cazzola, et al.
Published: (2018-05-01)